Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T, Ferhanoğlu B. Öztürk E, et al. Among authors: yalniz ff. Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26294270 No abstract available.
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: yalniz ff. Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10. Br J Haematol. 2014. PMID: 24815307 Free article. No abstract available.
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Ferhanoglu B, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: yalniz ff. Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18. Leuk Res. 2014. PMID: 24832371
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: yalniz ff. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28847475
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Ongoren S, et al. Among authors: yalniz ff. Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Hematology. 2018. PMID: 28990873 Review.
Copy-number variations in adult patients with chronic immune thrombocytopenia.
Yucesan E, Hatirnaz Ng O, Yalniz FF, Yilmaz H, Salihoglu A, Sudutan T, Eskazan AE, Ongoren S, Baslar Z, Soysal T, Ozbek U, Sayitoglu M, Ar MC. Yucesan E, et al. Among authors: yalniz ff. Expert Rev Hematol. 2020 Nov;13(11):1277-1287. doi: 10.1080/17474086.2020.1819786. Epub 2020 Sep 23. Expert Rev Hematol. 2020. PMID: 32885695
Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literature.
Cirakoglu A, Kuru RD, Yilmaz S, Deviren A, Ongoren S, Yalniz FF, Keskin D, Eskazan AE, Salihoglu A, Cem Ar M, Sahin S, Aydin Y, Hacihanefioglu S, Baslar Z, Soysal T, Arguden YT. Cirakoglu A, et al. Among authors: yalniz ff. Afr Health Sci. 2022 Sep;22(3):183-191. doi: 10.4314/ahs.v22i3.21. Afr Health Sci. 2022. PMID: 36910358 Free PMC article.
29 results